Aurinia Pharmaceuticals (NASDAQ:AUPH) Announces Quarterly Earnings Results, Beats Expectations By $0.08 EPS

Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP posted its quarterly earnings data on Monday. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.08 by $0.08, Zacks reports. Aurinia Pharmaceuticals had a negative return on equity of 4.41% and a negative net margin of 10.23%. The business had revenue of $62.47 million during the quarter, compared to the consensus estimate of $61.06 million. Aurinia Pharmaceuticals updated its FY 2025 guidance to EPS.

Aurinia Pharmaceuticals Stock Performance

AUPH stock traded up $0.30 during trading hours on Thursday, reaching $8.15. The stock had a trading volume of 1,680,404 shares, compared to its average volume of 1,339,588. The stock has a 50-day simple moving average of $8.02 and a 200 day simple moving average of $8.23. Aurinia Pharmaceuticals has a fifty-two week low of $5.11 and a fifty-two week high of $10.67. The stock has a market capitalization of $1.11 billion, a PE ratio of -54.33 and a beta of 1.16. The company has a debt-to-equity ratio of 0.17, a current ratio of 5.60 and a quick ratio of 5.11.

Insider Transactions at Aurinia Pharmaceuticals

In other Aurinia Pharmaceuticals news, CFO Joseph M. Miller sold 61,859 shares of Aurinia Pharmaceuticals stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $8.00, for a total value of $494,872.00. Following the completion of the sale, the chief financial officer now owns 633,515 shares in the company, valued at $5,068,120. The trade was a 8.90% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Greg Keenan sold 12,239 shares of the stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $8.00, for a total transaction of $97,912.00. Following the transaction, the insider now owns 161,789 shares in the company, valued at approximately $1,294,312. The trade was a 7.03% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 343,898 shares of company stock worth $2,753,094 in the last ninety days. Insiders own 4.30% of the company's stock.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Aurinia Pharmaceuticals stock. Royal Bank of Canada boosted its stake in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) TSE: AUP by 65.3% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 367,661 shares of the biotechnology company's stock after acquiring an additional 145,179 shares during the period. Royal Bank of Canada owned 0.27% of Aurinia Pharmaceuticals worth $2,956,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 36.83% of the company's stock.

Wall Street Analyst Weigh In

Separately, StockNews.com upgraded shares of Aurinia Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Thursday, March 27th.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.